KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Non Operating Income: 2018-2024

Historic Other Non Operating Income for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to -$1.5 million.

  • Royalty Pharma's Other Non Operating Income rose 4.78% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year increase of 52.58%. This contributed to the annual value of -$1.5 million for FY2024, which is 92.97% up from last year.
  • Latest data reveals that Royalty Pharma reported Other Non Operating Income of -$1.5 million as of FY2024, which was up 92.97% from -$21.7 million recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Other Non Operating Income ranged from a high of -$1.5 million in FY2024 and a low of -$32.8 million during FY2020.
  • Moreover, its 3-year median value for Other Non Operating Income was -$14.8 million (2022), whereas its average is -$12.7 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first slumped by 8,451.40% in 2020, then soared by 92.97% in 2024.
  • Royalty Pharma's Other Non Operating Income (Yearly) stood at -$32.8 million in 2020, then skyrocketed by 82.70% to -$5.7 million in 2021, then tumbled by 159.86% to -$14.8 million in 2022, then crashed by 47.32% to -$21.7 million in 2023, then soared by 92.97% to -$1.5 million in 2024.